|
|
Sarah
L. Scarpace, Pharm.D., BCOP
Associate Professor and Vice Chair
Department of Pharmacy Practice
(o) 518.694.7226
Education:
Pharm.D., Univeristy at Buffalo
Oncology pharmacy residency, Roswell Park Cancer Institute, Buffalo, NY
Courses Taught at ACPHS:
PHM 535: Cancer Screening, prevention, and Early Detection
Oncology Advanced Ambulatory Care
Recitation
Pharmacotherapy 4 Lecture and Pharmacotherapy Recitation
Seminar 2
Research Interests:
My research endeavours are clinical-practice based and focus on optimizing patient-centered care of the oncology patient, specifically regarding supportive care (especially anemia, neutropenia, and antiemesis) and public health initiatives to improve cancer screening, prevention, and early detection.
Recent Publications:
Scarpace, Sarah L. Utility of a website to improve the clerkship experience and enhance clinical team collaboration. Poster presentation. 2006 AACPHS Annual Meeting. July 8- 12, 2006. San Diego, CA.
Stack, N; Zeolla, M: Scarpace, SL; Brodeur, M; Grabe, D. Collaborative development of a longitudinal patient case in a team-taught introductory pharmacotherapy module. Poster presentation. 2006 AACPHS Annual Meeting. July 8 - 12, 2006. San Diego, CA.
Ferro, S; Cosler, L; Wolff, D; Poniewierski, M; Culakova, E; Scarpace, S; Khovana, A; Lyman GH. Variation in the cost of colorectal cancer. Poster presentation. 2006 ASCO Annual Meeting. June - 6, 2006. Atlanta, GA.
Zielonka, M; Scarpace, SL. Efficacy of standard treatment used for chemotherapy-induced emesis in the VAMC population. Oral presentation at the 2006 ASHP Eastern States Conference. May 11 - 12, 2006. Baltimore, MD.
Scholarship:
Scarpace SL, Dominelli A. Cancer
screening, prevention, and early detection course as a vehicle for Roadmap
2015. Presented at the American Association of Colleges of Pharmacy (AACP)
annual meeting, school poster session, July 19-23, 2008, Chicago, IL.
Adamczyk R, Scarpace SL. Do HMG-CoA reductase inhibitors increase the risk of LFT elevations in patients treated with docetaxel? Poster presentation during the Hematology/Oncology Pharmacists Association (HOPA)/ International Society of Oncology Pharmacy Practitioners (ISOPP) 2008 Joint Annual Conference, June 18-21, 2008, Anaheim, CA.
Murdico AT, Scarpace SL. Does following
the national comprehensive cancer network (NCCN) treatment guidelines for
anemia improve chemotherapy dose intensity (CDI) when treating various cancer
types? Poster presentation 2007 HOPA Annual Meeting, Residents/Fellows Poster
session. June 14 – 16, 2007. Denver, CO.
Scarpace SL, Ramanathan N, Ramanarayanan
J, Jackson AI, Pasquale D. Administration of greater than 2 cycles of fludarabine
(FLU) increases the risk of infection (ROI) independent of other risk factors.
Poster presentation 2007 ACCP Spring Practice and Research Forum. April 23
– 25, 2007. Memphis, TN.
Ramanarayanan J and Scarpace SL.
Acute drug-induced hepatitis due to erlotinib. Journal of the Pancreas 2007;
8(1): 39-43.
Pasquale D, Ramanathan N, Scarpace SL, Hung N, Jackson AI, and Ramanarayanan
J. Individualized Dosing of Fludarabine for Low Grade Lymphoproliferative
Disorders Results in Administration of Less Medication with Fewer Infections
and Equivalent Survival. Blood 2006; 108(11s2): 332b.
Other (patent, textbook, clinical affiliations, etc.):
NENYSCHP (member since 2004; delegate 2005 and 2006); HOPA (member since 2005); ASHP (member since 2002); ASCO (affiliate member since 2002); ACCP (member since 2004; full member since 2005); AACPHS (member since 2004)
Reviewer - Pharmacotherapy - since 2005
Reviewer - Pharmacotherapy Essentials, 1st edition, Breast and Prostate
cancer chapters. 2006